Ptc Therapeutics, Inc. (PTCT) · Aug 28, 2026 · Acquisition
$111M ST-920 acquisition — $111M upfront plus up to $100M in milestones
PTC formalizes its $111M acquisition of Sangamo’s ST-920 gene therapy, but the deal still needs bankruptcy-court approval before closing.
The filing formalizes a deal the market already knew was coming. PTC had already announced on August 12, 2026 that it was the winning bidder for ST-920 in Sangamo’s bankruptcy auction, so this agreement is confirmation rather than a fresh strategic surprise. 〔0〕
The economics are now defined: $111 million upfront, with $100 million contingent on FDA approvals. The milestone structure places $80 million on accelerated approval and $20 million on full approval, meaning most of the additional consideration depends on regulatory execution rather than being paid immediately. (Item 1.01)
The immediate read is neutral because the headline terms were already disclosed, while closing risk remains. The transaction still requires Bankruptcy Court authorization, antitrust clearance and other customary conditions; either party can terminate if it has not closed by October 15, 2026, subject to exceptions. (Item 1.01) 〔1〕
The next information point is procedural, not financial. A Bankruptcy Court hearing to approve the acquisition is scheduled for September 10, 2026, making court approval the key near-term catalyst. (Item 1.01) 〔2〕
Bankruptcy Court approval hearing, September 10, 2026
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!